As of December 31, 2025 and 2024, we had $28.9 million and $36.9 million, respectively, of long-term inventory included within other assets in our consolidated balance sheets as we anticipate it being consumed beyond our normal operating cycle.


	As of December 31,
(In thousands)	2025		2024
Buildings	$	297,618	$	294,508
Leasehold improvements	241,077		236,686
Laboratory equipment	140,943		121,957
Manufacturing equipment	48,935		49,062
Computer equipment and software	45,270		42,534
Furniture and fixtures	11,970		11,647
Land	9,080		9,080
Construction in progress	40,954		7,674
	835,847		773,148
Less: accumulated depreciation	(322,700)		(270,364)
Total property, plant and equipment, net	$	513,147	$	502,784


	As of December 31,
(In thousands)	2025		2024
Product rebates and discounts	$	400,147	$	361,816
Compensation and related	257,197		214,399
Preclinical, clinical trial and manufacturing	104,097		75,815
Licensing and collaboration agreements	258,856		92,313
Consulting and professional services	34,328		19,974
Other	25,572		29,375
Total accrued expenses	$	1,080,197	$	793,692

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our consolidated balance sheets to the totals of these amounts shown in the consolidated statements of cash flows:


	As of December 31,
(In thousands)	2025		2024		2023
Cash and cash equivalents	$	1,657,250	$	966,428	$	812,688
Total restricted cash included in other assets	1,557		2,224		2,196
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows	$	1,658,807	$	968,652	$	814,884


(In thousands)	Loss on Investment in Joint Venture		Defined Benefit Pension Plans, Net of Tax		Unrealized Gains (Losses) from Debt Securities		Foreign Currency Translation Adjustment		Total Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2023	$	(32,792)	$	(2,753)	$	1,548	$	10,622	$	(23,375)
Other comprehensive (loss) income before reclassifications	—		(1,613)		3		(9,643)		(11,253)
Amounts reclassified from other comprehensive (loss) income	—		117		(7)		—		110
Net other comprehensive loss	—		(1,496)		(4)		(9,643)		(11,143)
Balance as of December 31, 2024	(32,792)		(4,249)		1,544		979		(34,518)
Other comprehensive income before reclassifications	—		531		3,353		11,624		15,508
Amounts reclassified from other comprehensive income	—		450		(1,537)		—		(1,087)
Net other comprehensive income	—		981		1,816		11,624		14,421
Balance as of December 31, 2025	$	(32,792)	$	(3,268)	$	3,360	$	12,603	$	(20,097)

Amounts reclassified out of accumulated other comprehensive loss relate to settlements of marketable debt securities and amortization of our pension obligation which are recorded as other income (expense), net in the consolidated statements of operations and comprehensive income (loss).